Screener
Neurocrine Biosciences NBIX Common stock, par value (in dollars per share)
Common stock, par value (in dollars per share) at other companies
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.
The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000914475-26-000026
| (in millions, except per share data) | March 31,2026 | December 31,2025 |
|---|---|---|
| Total liabilities | 1,498.8 | 1,378.4 |
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 5.0 shares authorized; no shares issued and outstanding | — | — |
| Common stock, $0.001 par value; 220.0 shares authorized; 100.6 and 100.1 shares issued and outstanding, respectively | 0.1 | 0.1 |
| Additional paid-in capital | 2,817.3 | 2,792.2 |
| Accumulated other comprehensive income | 0.4 | 13.1 |
| Retained earnings | 589.6 | 447.7 |
| Total stockholders’ equity | 3,407.4 | 3,253.1 |
Item 1. Financial Statements
FAQ
- What is Neurocrine Biosciences's common stock, par value (in dollars per share)?
- Neurocrine Biosciences (NBIX) reported common stock, par value (in dollars per share) of $0 in Q1 2026.
- How has Neurocrine Biosciences's common stock, par value (in dollars per share) changed year-over-year?
- Neurocrine Biosciences's common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0 to $0.
- What is the long-term trend for Neurocrine Biosciences's common stock, par value (in dollars per share)?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's common stock, par value (in dollars per share) has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.
Ask your AI about Neurocrine Biosciences's common stock, par value (in dollars per share).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude